The use of methotrexate in conservative treatment of placenta accreta spectrum disorders.

Abstract

Aim of the study: This article reports on a series of patients with placenta accreta spectrum (PAS) disorder who were treated conservatively with Methotrexate (MTX) administration with or without embolization. We investigate whether there is a place for MTX in conservative treatment of PAS.Methods: We present a single-center retrospective case series of five patients. In all patients, diagnosis was unexpected and not made prenatally.Conclusion: The benefits should be weighed against the possible drug toxicity. Today high-quality evidence is lacking. PAS covers a broad spectrum of pathology, standardization in prenatal and postnatal diagnosis can help to compare evidence on treatment.

• Authors: Caroline Gregoir, Ben De Becker, Jan Hauspy, Tina Vanderheyden, Philip Loquet
• Journal: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (J Matern Fetal Neonatal Med) Vol. 35 Issue 25 Pg. 7514-7517 (Dec 2022) ISSN: 1476-4954 [Electronic] England
• PMID: 34278931 (Publication Type: Journal Article)

Chemical References

• Methotrexate

Topics

• Pregnancy
• Female
• Humans
• Placenta Accreta (drug therapy, diagnosis)
• Methotrexate (therapeutic use)
• Retrospective Studies
• Conservative Treatment
• Embolization, Therapeutic